Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Malignant pleural mesothelioma (MPM) is an aggressive cancer, associated with poor prognosis. We assessed the feasibility of patient-derived cell cultures to serve as an ex vivo model of MPM. Patient-derived MPM cell cultures (n=16) exhibited stemness features and reflected intratumour and interpatient heterogeneity. A subset of the cells were subjected to high-throughput drug screening and coculture assays with cancer-specific cytotoxic T cells and showed diverse responses. Some of the biphasic MPM cells were capable of processing and presenting the neoantigen SSX-2 endogenously. In conclusion, patient-derived MPM cell cultures are a promising and faithful ex vivo model of MPM.

Original publication

DOI

10.1136/thoraxjnl-2020-215027

Type

Journal article

Journal

Thorax

Publication Date

11/2020

Volume

75

Pages

1004 - 1008

Keywords

mesothelioma, pleural disease, Biomarkers, Tumor, Cell Culture Techniques, Genes, Tumor Suppressor, High-Throughput Screening Assays, Humans, Immunotherapy, Mesothelioma, Malignant, Mutation, Pleural Neoplasms, Tumor Cells, Cultured, Whole Genome Sequencing